▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Samsung BioLogics said on June 21 products manufactured from its production line here won approval from the Canadian drug authority. The Korean pharmaceutical company said Health ...
[THE INVESTOR] The Securities and Futures Commission is wrapping up over a month-long review of Samsung BioLogics’s controversial accounting practices that could put the 27 trillion won (US$24.30 bil...
[THE INVESTOR] Daewoong Pharmaceutical said on June 19 it has received a Good Manufacturing Practice certificate from the European Medicines Agency for its facility for self-developed botulinum toxi...
[THE INVESTOR] GC Pharma said on June 19 that it has entered an agreement with Yuhan to co-develop rare disease treatments. The drug makers expect GC Pharma’s experience in developing orphan drugs ...
[THE INVESTOR] Celltrion said on July 18 it has made a resubmission to the US Food and Drug Administration to receive marketing approval for CT-P6, a proposed biosimilar to Roche’s breast cancer tre...
[THE INVESTOR] Daewoong Pharmaceuticals said on June 18 it has completed restructuring its research and development organization to hasten new drug development including diabetes and stem cell thera...
[THE INVESTOR] Korea’s Medytox is expected to receive marketing authorization for its botulinum toxin Neuronox in China before July next year, a local stock brokerage firm said on June 18. “Medytox...
[THE INVESTOR] The Securities and Futures Commission is planning to look into the financial statements of contract drugmaker Samsung BioLogics before 2015, which is when the firm posted the controve...
[THE INVESTOR] The financial regulator on June 12 held an extraordinary meeting to discuss allegations of an accounting breach at Samsung BioLogics. The latest meeting is aimed at giving financi...
[THE INVESTOR] Korean prosecutors said on June 12 they have raided the headquarters of biotech firm Nature Cell over suspected manipulation of its share price. Investigators from the Seoul Southern...
[THE INVESTOR] Korea’s state-run pension fund said on June 12 it has reduced its stake in Hyundai Glovis, a logistics arm under Hyundai Motor Group, to less than 10 percent, following the group’s de...
[THE INVESTOR] Korea’s Mirae SCI said on June 12 it has secured financing from the Yozma Group to create a biotechnology-focused joint venture with the Israel-based venture capital firm here. Yozma...
[THE INVESTOR] Korea’s largest pharmaceutical firm Yuhan is accelerating its investment in biotech companies in a bid to bolster its new drug portfolio for treating oncology and endocrinology. The ...
[THE INVESTOR] An affiliate of Korean biopharmaceutical firm Celltrion said on June 11 that the biosimilar drug Truxima is now available in 18 European countries. Celltrion Healthcare, which han...
[THE INVESTOR] Celltrion Healthcare said on June 8 that a subcutaneous formulation of its anti-inflammatory therapy Remsima, or CT-P13, demonstrated efficacy and safety comparable to the Remsima in...
Samsung to miss 350 million smartphone shipment goal
Naver to invest in Sequoia’s new venture fund: report
FTC chief vows to cooperate with EU to handle issues in Korea
Samsung to sell set-top box unit
Samsung holds global strategy meetings
Korea to launch K-pop coins, blockchain platform for hallyu fans
Big Hit investor SV Investment to make KOSDAQ debut next month
CJ considers IPO of Schwan’s after acquisition: report
June 24, 2018
